Sadanandam has classified different tumor types with different prognostic, cell-of-origin/phenotypes and therapeutic responses including pancreatic and colorectal tumours and stroma (in multiple Nature Medicines, Cancer Discovery and other reputed journals). Recently, he has published studies showing how to develop and use clinically relevant biomarker assays in gastrointestinal cancers. He also has shown how personaliseed preclinical trials can be done using in vitro and in vivo models. These pioneering studies are being explored by clinicians and cancer researchers for potential applications for patient benefits